123 Results for "

MI

" in MedChemExpress (MCE) Product Catalog:
Products (123)

123 Results for "MI" in MCE Product Catalog:

18
18 Publications Verification
Cat. No.: HY-143218
CAS No.: 1245606-71-6
Purity:  98.05%
Synonyms: Tetraphenylethene maleiMIde
TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasites Plasmodium falciparum .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-18100A
CAS No.: 75136-54-8
PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC50 of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-16925
CAS No.: 1857417-13-0
Research Areas:  

Cancer

MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-12276
CAS No.: 1047953-91-2
Purity:  99.73%
Target:  

MALT1

Research Areas:  

Cancer

MALT1 inhibitor MI-2 is a MALT1 inhibitor (IC50=5.84 μM). MALT1 inhibitor MI-2 binds directly to MALT1, irreversibly suppresses protease function and is accompanied by NF-κB reporter activity suppression, c-REL nuclear localization inhibition, and NF-κB target gene downregulation. MALT1 inhibitor MI-2 shows nontoxic to animals .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-17493
CAS No.: 1303607-07-9
Target:  

MDM-2/p53 Apoptosis

Research Areas:  

Neurological Disease Cancer

MI-773 is an orally active, selective MDM2-p53 interaction inhibitor with a Ki of 0.88 nM for MDM2. MI-773 blocks the MDM2-TP53 interaction. MI-773 potently activates p53. MI-773 induces Apoptosis. MI-773 causes tumor regression in xenograft models of adenoid cystic carcinoma. MI-773 exhibits anticancer effects in neuroblastoma. MI-773 TFA can be used for the research of adenoid cystic carcinoma .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-17493A
CAS No.: 1303609-37-1
Target:  

MDM-2/p53 Apoptosis

Research Areas:  

Neurological Disease Cancer

MI-773 TFA is an orally active, selective MDM2-p53 interaction inhibitor with a Ki of 0.88 nM for MDM2. MI-773 TFA blocks the MDM2-TP53 interaction. MI-773 TFA potently activates p53. MI-773 TFA induces Apoptosis. MI-773 TFA causes tumor regression in xenograft models of adenoid cystic carcinoma. MI-773 TFA exhibits anticancer effects in neuroblastoma. MI-773 TFA can be used for the research of adenoid cystic carcinoma .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-141537
CAS No.: 1638200-22-2
Purity:  98.71%
Research Areas:  

Inflammation/Immunology

ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-18986
CAS No.: 1303607-60-4
Synonyms: MI-77301
Research Areas:  

Cancer

SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a Ki of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-15222
CAS No.: 1271738-62-5
Purity:  99.81%
Research Areas:  

Cancer

Menin-MLL inhibitor MI-2 is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-19810
CAS No.: 1857417-10-7
Research Areas:  

Cancer

MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC50 of 21 nM.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-125858
CAS No.: 1410737-34-6
Purity:  99.72%
Research Areas:  

Cancer

MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-136360
CAS No.: 2134169-43-8
Purity:  98.03%
Research Areas:  

Cancer

MI-3454 is an orally active, highly potent and selective menin-MLL1 interaction inhibitor with an IC50 of 0.51 nM. MI-3454 inhibits proliferation, induces differentiation and complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia through downregulation of key genes involved in leukemogenesis .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-106262B
Purity:  99.73%
Synonyms: KAI-9803 hydrochloride; BMS-875944 hydrochloride
Target:  

PKC

Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-125858A
CAS No.: 1410737-35-7
Purity:  97.47%
Research Areas:  

Cancer

MI-1061 TFA is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19809
CAS No.: 1628317-18-9
Research Areas:  

Cancer

MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0353
CAS No.: 13657-68-6
Synonyms: (+)-Curdione
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108350
CAS No.: 1454920-20-7
Purity:  99.92%
Research Areas:  

Cancer

MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (Kd=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15223
CAS No.: 1271738-59-0
Purity:  99.58%
Synonyms: Menin-MLL inhibitor 3
Research Areas:  

Cancer

MI-3 (Menin-MLL inhibitor 3) is a potent and high affinity menin-MLL inhibitor with an IC50 of 648 nM and a Kd of 201 nM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-19319
CAS No.: 1628316-74-4
MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC50 of 31 nM and a Kd of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99891
CAS No.: 339086-79-2
Synonyms: Hu23F2G

Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .
loading...
    loading...